John Sinden

This inventor holds 10 USPTO granted patents and 9 published patent applications, plus 6 CIPO patents and 9 EPO patents. Top assignee: Reneuron, Inc.. Active years: 2006-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John Sinden. Retrieved from https://idiyas.com/inventor/john-sinden

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 (Patent Applications = 9)

% Patents Active = 60.0

CIPO Patents = 6 (Patent Applications = 8)

EPO Patents = 9 (Patent Applications = 13)

Average Co-Inventor Count = 3.4

ph-index = 3

Forward Citations = 24(Granted Patents)

Location History:

London, GB (2006 - 2008)
Surrey, GB (2008 - 2016)
Guildford, GB (2015 - 2019)

Company Filing History:

10 out of 18

Reneuron, Inc.

patents

Years Active: 2006-2019

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10406182 - Stem cell microparticles and miRNA (2019-09-10),

2. 9629879 - Therapeutic use of neural stem cells (2017-04-25),

3. 9410122 - Treatment of limb ischemia (2016-08-09),

4. 9265795 - Cellular compositions for use in therapy (2016-02-23),

5. 8932577 - Treatment of limb ischemia (2015-01-13),

6. 7666672 - Cell lines (2010-02-23),

7. 7419827 - Cell lines (2008-09-02),

8. 7416888 - Cell lines (2008-08-26),

9. 7371374 - Neural transplantation using pluripotent neuroepithelial cells (2008-05-13),

10. 7048921 - Neural transplantation using pluripotent neuroepithelial cells (2006-05-23),

Title: Innovations of John Sinden in Stem Cell Research

Introduction

John Sinden is a prominent inventor based in Guildford, GB, known for his significant contributions to the field of stem cell research. With a total of 10 patents to his name, Sinden has made remarkable strides in developing innovative therapies for various cancers and neurological disorders.

Latest Patents

Among his latest patents, Sinden has focused on stem cell microparticles and miRNA. This invention pertains to the isolation of stem cell microparticles and miRNA derived from these microparticles, particularly neural stem cell microparticles. These innovations are aimed at therapeutic applications in treating cancers such as glioma, melanoma, breast cancer, pancreatic cancer, and prostate cancer. The stem cell microparticles are typically exosomes or microvesicles, which may be sourced from a neural stem cell line, specifically the conditionally-immortalized CTX0E03 stem cell line.

Career Highlights

Sinden's career is marked by his work at Reneuron, Inc., where he has been instrumental in advancing research in stem cell therapies. His inventions have the potential to revolutionize treatment options for patients suffering from various disorders associated with elevated levels of pro-inflammatory cytokines, including unipolar and bipolar depression, schizophrenia, obsessive-compulsive disorder, and autism.

Collaborations

Throughout his career, Sinden has collaborated with notable colleagues such as Kenneth Pollock and Paul Stroemer, contributing to the advancement of innovative therapies in the field of stem cell research.

Conclusion

John Sinden's work in stem cell research exemplifies the impact of innovation in medicine. His patents and ongoing research continue to pave the way for new therapeutic approaches to complex health issues.

Profile summary based on public USPTO records.